Latest News
FDA approves Lilly’s expanded indication for Jaypirca (pirtobrutinib) for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
Details >FDA Approves AstraZeneca's Imfinzi (durvalumab) for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Details >FDA Approves Merck's KEYTRUDA® (pembrolizumab) with enfortumab vedotin-ejfv for Muscle Invasive Bladder Cancer
Details >FDA Approves Amgen’s IMDELLTRA® (tarlatamab-dlle) in Extensive Stage Small Cell Lung Cancer
Details >FDA Approves AstraZeneca’s Koselugo (selumetinib), for the Treatment of Adult Patients with Neurofibromatosis Type 1 (NF1) who have Symptomatic, Inoperable Plexiform
Details >FDA Approves Genmab’s EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
Details >Oral Chemotherapy Copay and Coinsurance Cap Coming Jan. 1, 2026
Blue Cross Blue Shield of Michigan Announcement
Details >Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!
